Prion-like propagation represents one of the most transformative concepts in neurodegenerative disease research, explaining how protein pathology spreads throughout the brain in a predictable pattern. Originally discovered in prion diseases like Creutzfeldt-Jakob disease, the principle of template-guided protein misfolding and cell-to-cell transmission has now been extended to Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and frontotemporal dementia[1].
This mechanism explains the characteristic spreading patterns observed in postmortem brain tissue, where pathology advances along anatomically connected neural networks rather than appearing randomly throughout the brain. The recognition that multiple neurodegenerative diseases share this propagation mechanism has fundamentally changed our understanding of disease progression and opened new therapeutic avenues[2].
All prion-like proteins share the ability to convert normal, native proteins into their misfolded conformations through a process termed "templated nucleation"[3]. The misfolded protein serves as a template that catalyzes the conformational conversion of normal proteins:
This templated conversion distinguishes prion-like propagation from classical protein aggregation, as the presence of a seed dramatically accelerates the nucleation process and ensures strain-specific conformations are maintained during propagation[4].
Tau oligomers represent the most toxic species in Alzheimer's disease and play a critical role in prion-like spreading[5]. Unlike mature neurofibrillary tangles (NFTs), tau oligomers are soluble, prefibrillar aggregates that:
Research has demonstrated that tau oligomers can be detected in cerebrospinal fluid and interstitial fluid, providing evidence for their extracellular presence and potential for intercellular transmission[6]. The oligomeric species bind to neuronal membranes and are internalized through receptor-mediated endocytosis, facilitating seed propagation to connected neurons[7].
The propagation of pathological protein seeds occurs through multiple coordinated mechanisms:
Cellular Release Pathways:
Cellular Uptake Pathways:
Distinct conformational variants (strains) of the same protein can encode different disease phenotypes[11]. These strains represent alternative misfolded states that:
In Alzheimer's disease, tau strains isolated from different brain regions show distinct fibril morphologies and seeding activities, suggesting regional variation in strain composition[12]. Similarly, α-syn strains differ between Parkinson's disease and multiple system atrophy, with MSA-derived strains showing greater oligodendrocyte tropism and faster propagation rates[13].
Amyloid-beta (Aβ) propagation in Alzheimer's disease follows the prion-like template mechanism, though with some unique features compared to other neurodegenerative proteins[14]. Aβ seeds can template the misfolding of endogenous Aβ, promoting plaque formation in previously unaffected brain regions.
While most commonly applied to tau pathology, Aβ plaque deposition follows a staging system:
The prion-like nature of Aβ is supported by:
Tau propagation represents one of the best-characterized prion-like mechanisms in neurodegeneration[17]. Hyperphosphorylated tau dissociates from microtubules, aggregates into paired helical filaments (PHFs), and spreads through interconnected brain regions.
Tau neurofibrillary tangles follow a highly predictable spreading pattern:
Tau spreads through multiple mechanisms:
| Mechanism | Description | Evidence |
|---|---|---|
| Synaptic activity | Tau is released from presynaptic terminals during neuronal activity | In vitro studies show activity-dependent release[18] |
| Extracellular vesicles | Exosomal tau transport between cells | Exosomal tau detected in CSF and media[19] |
| Tunneling nanotubes | Direct intercellular transfer via TNTs | Transfer observed in co-culture systems[20] |
| Non-synaptic release | Activity-dependent release independent of synapses | Microdialysis studies in human brain[21] |
Understanding tau propagation has enabled development of novel therapeutic strategies:
Alpha-synuclein (α-syn) propagation underlies Parkinson's disease progression and defines the synucleinopathies including PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)[23]. Unlike tau and Aβ, α-syn propagation involves both inside-out and outside-in mechanisms.
α-syn pathology follows a bottom-up progression:
This staging explains the characteristic prodromal autonomic symptoms (constipation, REM sleep behavior disorder) preceding motor symptoms by years[24].
A critical distinction exists in α-syn strains between:
This strain difference may explain the divergent clinical presentations and treatment responses[25].
TDP-43 propagation occurs in ALS and most cases of frontotemporal dementia[26]. Unlike the extracellular proteins above, TDP-43 propagation is primarily a neuronal phenomenon with cytoplasmic mislocalization rather than extracellular transmission.
TDP-43 pathology spreads:
Huntingtin (HTT) aggregation in Huntington's disease involves polyglutamine (polyQ) expansion, creating a distinct prion-like mechanism[28]. While classical prion-like spreading is less established, evidence suggests template-assisted propagation.
Huntingtin pathology:
| Protein | Primary Disease | Braak-like Staging | Extracellular | Key Mechanism |
|---|---|---|---|---|
| Aβ | Alzheimer's | Yes (stages I-VI) | Yes | Plaque spreading |
| Tau | AD/FTD | Yes (stages I-VI) | Yes | Network-based |
| α-syn | PD/DLB/MSA | Yes (stages 1-6) | Yes | Synaptic transmission |
| TDP-43 | ALS/FTD | Yes | No | Corticospinal tract |
| HTT | Huntington's | No | Limited | Regional vulnerability |
Understanding prion-like propagation has led to therapeutic strategies:
The nucleation-dependent aggregation model provides the framework for understanding prion-like propagation[1:1]. This process involves:
Primary Nucleation:
Secondary Nucleation:
Surface-Catalyzed Nucleation:
The information content of prion-like strains resides in the three-dimensional structure of the aggregated protein[2:1]. This structural encoding:
Cryo-electron microscopy studies have revealed distinct amyloid conformations for different strains, with specific fold patterns correlating with clinical presentation[3:1].
Tunneling nanotubes (TNTs) represent a direct cell-to-cell communication channel that enables transfer of various cargoes including pathological proteins[4:1]. Key characteristics:
Extracellular vesicles (EVs) including exosomes and microvesicles serve as important vehicles for pathological protein spread[5:1]:
| Vesicle Type | Size | Biogenesis | Cargo |
|---|---|---|---|
| Exosomes | 30-150 nm | Endosomal pathway | α-syn, tau, Aβ |
| Microvesicles | 100-1000 nm | Plasma membrane shedding | TDP-43, HTT |
| Apoptotic bodies | 1000-5000 nm | Apoptosis | All proteins |
Synaptic activity plays a dual role in prion-like propagation:
Release mechanisms:
Uptake mechanisms:
The concentration of pathological proteins at synaptic terminals creates efficient propagation pathways along anatomically connected circuits[6:1].
Active and passive immunization strategies aim to neutralize extracellular pathological proteins:
Passive Immunotherapy:
Active Immunotherapy:
Targeted small molecules aim to:
Gene therapy offers potential for:
The field of prion-like propagation continues to evolve with several key research areas:
Prionlike Propagation of Neurodegeneration. Prion-Like Spread in Neurodegeneration. Nature Reviews Neurology. 2021. ↩︎ ↩︎
Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nature Neuroscience. Nat Neurosci. 2018. ↩︎ ↩︎
Soto C, Castilla J. The controversial prion-like phenomenon in neurodegeneration. FEBS Lett. FEBS Lett. 2011. ↩︎ ↩︎
Walker LC, Jucker M. The emergence of prion-like aggregation in neurodegenerative diseases. Acta Neuropathol. Acta Neuropathol. 2020. ↩︎ ↩︎
Lasagna-Reeves CA, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease brain. FASEB J. FASEB J. 2012. ↩︎ ↩︎
Yamada K, et al. In vivo detection of tau pathology in humans. J Nucl Med. J Nucl Med. 2015. ↩︎ ↩︎
Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. Nat Neurosci. 2016. ↩︎
Pooler AM, et al. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. EMBO Rep. 2013. ↩︎
Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. J Biol Chem. 2012. ↩︎
Abiega O, et al. Neuronal hyperactivity accelerates tau propagation and tau pathology. Nat Neurosci. Nat Neurosci. 2016. ↩︎
Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like aggregates. J Clin Invest. J Clin Invest. 2013. ↩︎
Kaufman SK, et al. Tau prion strains dictate patterns of neuropathology, progression and propagation. Acta Neuropathol. Acta Neuropathol. 2018. ↩︎
Prigent S, et al. Alpha-synuclein strains differ in disease phenotype. Acta Neuropathol. Acta Neuropathol. 2020. ↩︎
Hamaguchi T, et al. The presence of Aβ seeds in the brain. Acta Neuropathol. Acta Neuropathol. 2016. ↩︎
Kane MD, et al. Microglial activation by extracts of aggregated amyloid-beta. J Neurosci Res. J Neurosci Res. 2000. ↩︎
Jaunmuktane Z, et al. Evidence for amyloid-beta propagation in Creutzfeldt-Jakob disease. Acta Neuropathol. Acta Neuropathol. 2015. ↩︎
Mudher A, et al. What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathol Commun. Acta Neuropathol Commun. 2017. ↩︎
Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. J Exp Med. 2014. ↩︎
Wang Y, et al. The release and trans-synaptic transmission of tau via exosomes. Mol Neurodegener. Mol Neurodegener. 2017. ↩︎
Tardivel M, et al. Tunneling nanotube-mediated long-distance transfer of pathological tau. Cell Rep. Cell Rep. 2016. ↩︎
Bancher C, et al. Massie F. Tau in the brain and CSF. Acta Neuropathol. Acta Neuropathol. 2016. ↩︎
Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. Trends Mol Med. 2015. ↩︎
Bridi JC, Hirth F. Alpha-synuclein and synucleinopathies. J Parkinsons Dis. J Parkinsons Dis. 2018. ↩︎
Braak H, et al. Staging of the intracerebral inclusion body pathology. Acta Neuropathol. Acta Neuropathol. 2003. ↩︎
Peng C, et al. Cellular milieu for propagation of α-synuclein strains. J Exp Med. J Exp Med. 2018. ↩︎
Rascovsky K, et al. TDP-43 in the pathogenesis of ALS/FTD. Nat Rev Neurol. Nat Rev Neurol. 2020. ↩︎
Armakola M, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS models. Nat Neurosci. Nat Neurosci. 2012. ↩︎
Tattersfield AS, et al. Polyglutamine aggregation in Huntington disease. J Huntington Dis. J Huntingtons Dis. 2014. ↩︎
Ren PH, et al. Mutant huntingtin protein and its pathogenic significance. J Huntingtons Dis. J Huntingtons Dis. 2019. ↩︎
DeMattos RB, et al. Peripheral anti-Aβ antibody in transgenic mice. Neuron. Neuron. 2002. ↩︎